Evaluation of Anti-HBs Serum Levels and Pharmacokinetic Profile After Intravenous Administration of Niuliva, a New Hepatitis B Immunoglobulin, Following Liver Transplantation

Transplantation Proceedings

Volumn 41, Issue 10, 2009, Pages 4253-4258

  Mas, A ^a   Castells, L ^b   Abradelo, M ^d   Bernardos, A ^e   Paez A ^c   Woodward, M K ^c   Sousa, J M ^e  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c Instituto Grifols   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; NIULIVA; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HEPATITIS B; HUMAN; HYPOTENSION; IN VIVO STUDY; JAUNDICE; LIVER DISEASE; LIVER TRANSPLANTATION; MALE; MULTICENTER STUDY; OPEN STUDY; PHARMACOKINETICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT INFECTION; SEROCONVERSION; TREATMENT DURATION; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HUMANS; IMMUNOGLOBULINS; LIFE EXPECTANCY; LIVER TRANSPLANTATION; MIDDLE AGED; PATIENT SELECTION; PROSPECTIVE STUDIES; SAFETY; YOUNG ADULT;

EID: 71249155673     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.09.083     Document Type: Article

References (27)

1. Villamil F.G. Hepatitis B: progress in the last 15 years. Liver Transpl 8 10 Suppl 1 (2002) S59
2. Vierling J.M. Management of HBV infection in liver transplantation patients. Int J Med Sci 2 (2005) 41
3. Seehofer D., and Berg T. Prevention of hepatitis B recurrence after liver transplantation. Transplantation 80 1 Suppl (2005) S120
4. McGory R. Pharmacoeconomic analysis of HBV liver transplant therapies. Clin Transplant 14 Suppl 2 (2000) 29
5. Buti M., Mas A., Prieto M., et al. A randomized study comprising lamivudine monotherapy after a short course of hepatitis B immune glubulin (vid) and lamivudine with long-term lamivudine plus vid in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 38 (2003) 811
6. Dodson S.F., de Vera M.E., Bonham C.A., Geller D.A., Rakela J., and Fung J.J. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl 6 (2000) 434
7. Rizzetto M., and Marzano A. Posttransplantation prevention and treatment of recurrent hepatitis B. Liver Transpl 6 Suppl 2 (2000) S47
8. Polak W.G., Gladysz A., and Rotter K. Prevention of hepatitis B recurrence after liver transplantation. Ann Transplant 10 (2005) 11
9. Ferretti G., Merli M., Ginanni Corradini S., et al. Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. Transplant Proc 36 (2004) 535
10. Samuel D., Muller R., Alexander G., et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 329 (1993) 1842
11. Terrault N.A., Zhou S., Combs C., et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 24 (1996) 1327
12. Mutimer D. Review article: hepatitis B and liver transplantation. Aliment Pharmacol Ther 23 (2006) 1031
13. Shouval D., and Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 32 (2000) 1189
14. Wang Z.F., Zhu Z.J., and Shen Z.Y. Advances in prophylaxis and treatment of recurrent hepatitis B after liver transplantation. Hepatobiliary Pancreat Dis Int 4 (2005) 509
15. Tung B.Y., and Kowdley K.V. Hepatitis B and liver transplantation. Clin Infect Dis 41 (2005) 1461
16. Cirera I., Mas A., Salmerón J.M., et al. Reduced doses of hepatitis B immunoglobulin protect against hepatitis B virus infection recurrence after liver transplantation. Transplant Proc 33 (2001) 2551
17. Sanchez-Fueyo A., Rimola A., Grande L., et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B vaccination: a new strategy in the prophylaxis of hepatitis b virus recurrence after liver transplantation. Hepatology 31 (2000) 496
18. Angus P.W., McCaughan G.W., Gane E.J., Crawford D.H., and Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against post-transplantation hepatitis B. Liver Transpl 6 (2000) 429
19. Yao F.Y., Osorio R.W., Roberts J.P., et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 5 (1999) 491
20. Han S.H., Ofman J., Holt C., et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 6 (2000) 741
21. Moreno González E., Loinaz C., García I., et al. Liver transplantation in chronic viral B and C hepatitis. J hepatol 17 Suppl 3 (1993) S116
22. Mohanty S.R., and Cotler J.S. Management of hepatitis B in liver transplant patients. J Clin Gastroenterol 39 (2005) 58
23. Restrepo J.C., Rimola A., Mas A., et al. Administración prolongada de gammaglobulina hiperinmune antihepatitis B en pacientes con transplante hepático por hepatopatía por virus de la hepatitis B. Gastroenterol Hepatol 19 (1996) 491
24. Castells L. Recurrencia de la enfermedad no maligna tras el trasplante hepático: hepatitis B. Gastroenterol Hepatol 23 Suppl 1 (2000) 81
25. Hooman N., Rifai K., Hadem J., et al. Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. Liver Transpl 14 (2008) 435
26. Davis G.L., Nelson D., Terrault N., et al. Collaborative Antiviral Study Group: A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (civacir) in liver transplant recipients. Liver Transpl 11 (2005) 941
27. Adler R., Safadi R., Caraco Y., Rowe M., Etzioni A., Ashur Y., and Shouval D. Comparison of immune reactivity and pharmacokinetics of two hepatitis B immune globulins in patients after liver transplantation. Hepatology 29 (1999) 1299